肿瘤细胞治疗研究
英文原题：To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy.
表位编辑是一种有前景的策略，可保护造血细胞免受免疫治疗的清除。
表位编辑是一种有前景的策略，可保护造血细胞免遭免疫疗法清除。近期，Ji等人在《Cell Stem Cell》发表研究，将碱基编辑（BE）和先导编辑（PE）用于改变造血干细胞中的CD123表位，以配合CAR-T疗法治疗急性髓系白血病。
Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia. 1 .
MEMBER ACCOUNT
登录成功会直接打开下一页。
